Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, R.
Right arrow Articles by Medof, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, R.
Right arrow Articles by Medof, M. E.
[Cancer Research 61, 654-658, January 15, 2001]
© 2001 American Association for Cancer Research


Molecular Biology and Genetics

Glycophosphatidylinositol-anchored Protein Deficiency as a Marker of Mutator Phenotypes in Cancer1

Rui Chen, James R. Eshleman2, Robert A. Brodsky and M. Edward Medof3

Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106 [R. C., J. R. E., M. E. M.], and Johns Hopkins Oncology Center [R. A. B.], Johns Hopkins University, Baltimore, Maryland 21231

Phosphatidylinositol glycan-A (PIGA) is a gene that encodes an element required for the first step in glycosylphosphatidylinositol (GPI) anchor assembly. Because PIGA is X-located, a single mutation is sufficient to abolish cell surface GPI-anchored protein expression. In this study, we investigated whether mutation of the PIGA gene could be exploited to identify mutator (Mut) phenotypes in cancer. We examined eight Mut colon cancer lines and four non-Mut colon cancers as controls. In every case, flow cytometric analyses of cells sorted for low fluorescence after staining for GPI-linked CD59 and CD55 revealed negative peaks in the Mut lines but not in the controls. Single cell cloning of purged and sorted GPI-anchor- HCT116 cells and sequencing of the PIGA gene in each clone uniformly showed mutations. Pretreatment of the Mut lines with anti-CD55 or anti-CD59 antibodies and complement or with the GPI-anchor-reactive bacterial toxin aerolysin enriched for the GPI-anchor- populations. Expansion of purged GPI-anchor+ cells in the Mut lines and analyses using aerolysin in conjunction with flow cytometry yielded PIGA gene mutation frequencies of 10-5 to 10-4, values similar to the mutation frequencies of the hprt gene. This novel approach allows for the detection of as yet undescribed repair or replication defects and in addition to its considerably greater ease of use than existing techniques and in principle would not require the production of cell lines.




This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
M. Fanjul, L. Alvarez, and E. Hollande
Expression and Subcellular Localization of a 35-kDa Carbonic Anhydrase IV in a Human Pancreatic Ductal Cell Line (Capan-1)
J. Histochem. Cytochem., August 1, 2007; 55(8): 783 - 794.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Araten, D. W. Golde, R. H. Zhang, H. T. Thaler, L. Gargiulo, R. Notaro, and L. Luzzatto
A Quantitative Measurement of the Human Somatic Mutation Rate
Cancer Res., September 15, 2005; 65(18): 8111 - 8117.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.